---
title: Lung Nodule Intervention Cohort Study
nct_id: NCT05441202
overall_status: UNKNOWN
sponsor: Chinese Chronic Respiratory Disease Research Network
study_type: OBSERVATIONAL
primary_condition: Incident Lung Nodule
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05441202.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05441202"
ct_last_update_post_date: 2022-07-01
last_seen_at: "2026-05-12T07:11:04.813Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Lung Nodule Intervention Cohort Study

**Official Title:** The Efficacy of Transdermal Therapy for Lung nodule---an Real Word Observational Study

**NCT ID:** [NCT05441202](https://clinicaltrials.gov/study/NCT05441202)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 10000
- **Lead Sponsor:** Chinese Chronic Respiratory Disease Research Network
- **Conditions:** Incident Lung Nodule
- **Start Date:** 2022-01-01
- **Completion Date:** 2025-01-01
- **CT.gov Last Update:** 2022-07-01

## Brief Summary

Incident lung nodule is quite common in China. The major treatment method is long-term floolow up without a specific intervention. We aim to investigate the efficacy an safty of a novel transdermal therapy with Chinese herb. The study included two arms: one arm is routine treatment and another arm is routine treatment plus transdermal therapy. The study end point is the change of lung nodule size under CT scan.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* incident lung nodule patients

Exclusion Criteria:

* severe baseline conditions
```

## Interventions

- **transdermal therapy** (DEVICE) — transdermal therapy with Chinese medicine

## Primary Outcomes

- **change of lung nodule size** _(time frame: three months minimal)_ — change of lung nodule size before and after intervention

## Locations (1)

- Guang An Men Hospital, Beijing, Beijing Municipality, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.guang an men hospital|beijing|beijing municipality|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05441202.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05441202*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*